RemeGen Licenses Ophthalmic Drug RC28-E to Santen for Up to RMB 1.3b

China-headquartered RemeGen has entered into an exclusive out-licensing agreement with Japan's Santen Pharmaceutical for its VEGF/FGF dual-target fusion protein RC28-E in Greater China and seven Southeast Asian markets. The deal includes RMB 250 million upfront and up to RMB 1.045 billion in milestones and tiered royalties. RC28-E demonstrated significant improvements in best-corrected visual acuity and central subfield thickness reduction in Phase II diabetic macular oedema trials, with Phase III studies ongoing for wet age-related macular degeneration (wAMD) and diabetic macular oedema.

RemeGen retains global rights outside licensed territories and plans submissions for diabetic macular oedema in late 2025 and wAMD in mid-2026 in China. The partnership leverages Santen's ophthalmology expertise to commercialise this novel anti-angiogenic therapy, which simultaneously blocks the VEGF and FGF pathways implicated in retinal diseases affecting over 200 million patients worldwide.

According to PharmCube's NextBiopharm® database, this is the third out-licensing deal by RemeGen, its valuation paling in comparison with that of a transaction with Vor Biopharma. Click here to request a free trial for NextBiopharm®.

Daily News
Haisco Licenses PDE3/4 Inhibitor to AirNexis in Deal Exceeding USD 1 Billion
2026-01-13
MediLink Licenses B7-H3 ADC to Roche in New Exclusive Agreement
2026-01-13
Hengrui Gains First Global Approval for Anti-PD-L1×TGF-βRII Bispecific
2026-01-12
Lilly Collaborates with InduPro on in Bs/MsAb Deal Worth Up to USD 950m
2026-01-12
HemaCell Secures Additional Funding in Series B1 Within a Week
2026-01-06
Latest Report
Insights into China’s Innovative Drug R&D and Transaction Trends_PharmCube
Details